Related references
Note: Only part of the references are listed.Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide
MG Agadjanyan et al.
JOURNAL OF IMMUNOLOGY (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease
A Monsonego et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
Patients with Alzheimer disease have lower levels of serum antiamyloid peptide antibodies than healthy elderly individuals
ME Weksler et al.
EXPERIMENTAL GERONTOLOGY (2002)
Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
EM Sigurdsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Intraneuronal A beta 42 accumulation in human brain
GK Gouras et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
